EEEman Saleh El-Ashry

Eman Saleh El-Ashry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eman Saleh El-Ashry has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ameliorating effect of Cynara scolymus (artichoke) against thiamethoxam-induced hepatotoxicity in poultry

    by Amal Moktar, Magdy S. Amer, Aza E. Hassan, Ahmed Ateya, Eman Elashry

    This study investigated the effects of thiamethoxam (TMX), a neonicotinoid insecticide, on liver health in chickens and examined whether artichoke extract (ART) could offer protection. Forty-eight healthy chicks were divided into four groups: a control group given saline, a TMX group given TMX, a TMX + ART group given both TMX and ART and a protective ART + TMX group given ART first, then TMX. The results showed that artichoke extract significantly improved blood parameters and reduced liver damage markers compared to the TMX group. It also decreased oxidative stress and boosted antioxidant defenses. Gene expression analysis revealed that ART downregulated inflammatory markers in the liver. Histological examination confirmed that artichoke extract helped restore normal liver structure. Overall, artichoke extract effectively mitigated TMX-induced liver damage by reducing oxidative stress and improving biochemical and antioxidant markers.

  • The ameliorative effects of cinnamum zeylanicum extract on renal functions and oxidative stress against fluoxetine drug in male rats

    by Nada Hashem, Nabil Abu Heakal, Huda El-Emam, Eman Saleh El-Ashry, Mona M. Elghareeb

    Objective: To determine the effects of cinnamon against fluoxetine on renal function, lipid profiles and oxidative stress. Design: Randomized controlled study Animals: Thirty-twoalbino rats Procedures: Rats were allocated into four groups, control, FLX, Cin and FLX+ Cin group for 60 days. Blood samples were collected for measurement of kidney, liver function and lipid profiles. The left kidney was taken for determination of oxidative stress parameters, histopathological evaluation and detection of levels of caspase, renin and NRF2 genes. Procedures: FLX group administered fluoxetine 10 mg/kg Bwt. Cin group administered cinnamon 50 mg/kg body weight. FLX+ Cin group received fluoxetine at a concentration of 10 mg/kg body weight and after 30 minutes received cinnamon extract at dose of 50 mg/kg body weight.Results: Administration of fluoxetine exhibited a higher level of urea, uric acid and creatinine. Administration of Cin alone or with FLX improved kidney functions and antioxidant parameters. Marked increase was detected in FLX group compared to the Cin and Cin+FLX groups. Administration of cinnamon with fluoxetine leads to improvement in the lipid profiles. Moreover, there was a significant upregulation in renin and caspase 3 genes in FLX and FLX + Cin treated groups. The renal NRF2 was downregulated in FLX group and increased in Cin group. Histopathological pictures of renal sections showing tubular dilation with renal epithelial cells degeneration, necrosis and fibrosis in FLX group.Conclusion and clinical relevance: Cinnamon may be used to counteract the negative effect of fluoxetine drug on renal tissue.


  • Pharmacokinetic studies on Sulfamonomethoxine in rabbits

    by Magdy Amer, Mohamed Elsayed, S Kazawaki, W Fathy, Eman El-Ashry

    The present study was performed to determine the pharmacokinetics of sulfamonomethoxine (20mg/kg) in 5 rabbits after its oral and intravenous administration. Blood samples were collected immediately before (time 0) and at 0.08, 0.25, 0.5, 1, 3, 5 and 8 hours post-dosing to evaluate the pharmacokinetics of sulfamonomethoxine. Plasma sulfamonomethoxine concentrations were quantified with HPLC-UV, and plasma drug concentration versus time data after IV was best fitted to the two-compartment model, CHARacterized with the distribution phase (α) equaled to 2.05 h-1 with a distribution half-life [t0.5(α)] equaled to 0.61 h. The volume of distribution of (V1c) was 0.15 ml/kg., whereas the volume of distribution at a steady – state [Vdss] was 0.20 ml/kg, and the body clearance was 0.03 ml/ kg / h. After oral administration of SMM, plasma drug concentrations were best fitted to a two-compartment model, of which the mean half-life of absorption (t1/2ab) and elimination (t1/2β) were 0.02 and 1.99 h, respectively. The maximal absorption concentration (Cmax) was estimated as 114.06 µg/ml at 0.12 h, and the Area under the curve (AUC) was 340.42 µg/ml/h.